---
---

# 21 U.S.C., USLM ref /us/usc/t21/s379j–43

* Portions Copyright © 2016 the authors of the https://github.com/publicdocs project.
  Use of this file is subject to the NOTICE at [https://github.com/publicdocs/uscode/blob/master/NOTICE](https://github.com/publicdocs/uscode/blob/master/NOTICE)
* See the [Document Metadata](././../../../../../../..//README.md) for more information.
  This file is generated from historical government data; content and/or formatting may be inaccurate and out-of-date and should not be used for official purposes.

----------
----------

[Previous](./../../../../../../..//us/usc/t21/ch9/schVII/ptC/spt7/m__us_usc_t21_s379j–42.md) | [Next](./../../../../../../..//us/usc/t21/ch9/schVII/ptC/spt8/m__us_usc_t21_ch9_schVII_ptC_spt8.md) | [Root of Title](./../../../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs379j%E2%80%9343)

## § 379j–43. Reauthorization; reporting requirements

    (a) __Performance report__ 

        Beginning with fiscal year 2013, not later than 120 days after the end of each fiscal year for which fees are collected under this subpart, the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report concerning the progress of the Food and Drug Administration in achieving the goals identified in the letters described in section 301(b) of the Generic Drug User Fee Amendments of 2012 during such fiscal year and the future plans of the Food and Drug Administration for meeting the goals.

    (b) __Fiscal report__ 

        Beginning with fiscal year 2013, not later than 120 days after the end of each fiscal year for which fees are collected under this subpart, the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report on the implementation of the authority for such fees during such fiscal year and the use, by the Food and Drug Administration, of the fees collected for such fiscal year.

    (c) __Public availability__ 

        The Secretary shall make the reports required under subsections (a) and (b) available to the public on the Internet Web site of the Food and Drug Administration.

    (d) __Reauthorization__ 

        (1) __Consultation__ 

        In developing recommendations to present to the Congress with respect to the goals, and plans for meeting the goals, for human generic drug activities for the first 5 fiscal years after fiscal year 2017, and for the reauthorization of this subpart for such fiscal years, the Secretary shall consult with—

            (A) the Committee on Energy and Commerce of the House of Representatives;

            (B) the Committee on Health, Education, Labor, and Pensions of the Senate;

            (C) scientific and academic experts;

            (D) health care professionals;

            (E) representatives of patient and consumer advocacy groups; and

            (F) the generic drug industry.

        (2) __Prior public input__ 

        Prior to beginning negotiations with the generic drug industry on the reauthorization of this subpart, the Secretary shall—

            (A) publish a notice in the Federal Register requesting public input on the reauthorization;

            (B) hold a public meeting at which the public may present its views on the reauthorization, including specific suggestions for changes to the goals referred to in subsection (a);

            (C) provide a period of 30 days after the public meeting to obtain written comments from the public suggesting changes to this subpart; and

            (D) publish the comments on the Food and Drug Administration’s Internet Web site.

        (3) __Periodic consultation__ 

            Not less frequently than once every month during negotiations with the generic drug industry, the Secretary shall hold discussions with representatives of patient and consumer advocacy groups to continue discussions of their views on the reauthorization and their suggestions for changes to this subpart as expressed under paragraph (2).

        (4) __Public review of recommendations__ 

        After negotiations with the generic drug industry, the Secretary shall—

            (A) present the recommendations developed under paragraph (1) to the congressional committees specified in such paragraph;

            (B) publish such recommendations in the Federal Register;

            (C) provide for a period of 30 days for the public to provide written comments on such recommendations;

            (D) hold a meeting at which the public may present its views on such recommendations; and

            (E) after consideration of such public views and comments, revise such recommendations as necessary.

        (5) __Transmittal of recommendations__ 

            Not later than January 15, 2017, the Secretary shall transmit to the Congress the revised recommendations under paragraph (4), a summary of the views and comments received under such paragraph, and any changes made to the recommendations in response to such views and comments.

        (6) __Minutes of negotiation meetings__ 

            (A) __Public availability__ 

                Before presenting the recommendations developed under paragraphs (1) through (5) to the Congress, the Secretary shall make publicly available, on the Internet Web site of the Food and Drug Administration, minutes of all negotiation meetings conducted under this subsection between the Food and Drug Administration and the generic drug industry.

            (B) __Content__ 

                The minutes described under subparagraph (A) shall summarize any substantive proposal made by any party to the negotiations as well as significant controversies or differences of opinion during the negotiations and their resolution.

([June 25, 1938, ch. 675, § 744C][/us/act/1938-06-25/ch675/s744C], as added [Pub. L. 112–144, title III, § 303][/us/pl/112/144/s303], July 9, 2012, [126 Stat. 1022][/us/stat/126/1022].)

 __Termination of Section__ 

    For termination of section by [section 304(b) of Pub. L. 112–144][/us/pl/112/144/s304/b], see Effective and Termination Dates note set out below.

 __References in Text__ 

    Section 301(b) of the Generic Drug User Fee Amendments of 2012, referred to in subsec. (a), is [section 301(b) of Pub. L. 112–144][/us/pl/112/144/s301/b], which is set out as a note under [section 379j–41 of this title][/us/usc/t21/s379j–41].

 __Effective and Termination Dates__ 

[Pub. L. 112–144, title III, § 304(b)][/us/pl/112/144/s304/b], July 9, 2012, [126 Stat. 1024][/us/stat/126/1024], provided that: 

> “Section 744C of the Federal Food, Drug, and Cosmetic Act \[[21 U.S.C. 379j–43][/us/usc/t21/s379j–43]\], as added by section 303 of this Act, shall cease to be effective January 31, 2018.”

    Section effective Oct. 1, 2012, see [section 305 of Pub. L. 112–144][/us/pl/112/144/s305], set out as a note under [section 379j–41 of this title][/us/usc/t21/s379j–41].

----------

[Previous](./../../../../../../..//us/usc/t21/ch9/schVII/ptC/spt7/m__us_usc_t21_s379j–42.md) | [Next](./../../../../../../..//us/usc/t21/ch9/schVII/ptC/spt8/m__us_usc_t21_ch9_schVII_ptC_spt8.md) | [Root of Title](./../../../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs379j%E2%80%9343)

----------
----------

[/us/act/1938-06-25/ch675/s744C]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fact%2F1938-06-25%2Fch675%2Fs744C
[/us/pl/112/144/s303]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F112%2F144%2Fs303
[/us/stat/126/1022]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F126%2F1022
[/us/pl/112/144/s304/b]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F112%2F144%2Fs304%2Fb
[/us/pl/112/144/s301/b]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F112%2F144%2Fs301%2Fb
[/us/usc/t21/s379j–41]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs379j%E2%80%9341
[/us/pl/112/144/s304/b]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F112%2F144%2Fs304%2Fb
[/us/stat/126/1024]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F126%2F1024
[/us/usc/t21/s379j–43]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs379j%E2%80%9343
[/us/pl/112/144/s305]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F112%2F144%2Fs305
[/us/usc/t21/s379j–41]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs379j%E2%80%9341


